|
| Status |
Public on Jan 06, 2023 |
| Title |
CPI-0610, a potent and selective BET bromodomain inhibitor optimized for clinical development |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
SUDHL5 cells were treated with DMSO or 2.5 μM CPI203 for 4 hours, then processed for ChIP-Seq to obtain genome-wide binding changes for BRD4 upon treatment with a BET inhibitor.
|
| |
|
| Overall design |
Examination of BRD4 binding in the absence or presence of a BET inhibitor in SUDHL5 DLBCL cell line using ChIP-Seq
|
| |
|
| Contributor(s) |
Follmer NE, Hatton C, Bryant B, Sims III RJ |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Aug 05, 2015 |
| Last update date |
Jan 07, 2023 |
| Contact name |
Barbara M Bryant |
| E-mail(s) |
barbara.bryant@constellationpharma.com
|
| Organization name |
Constellation Pharmaceuticals
|
| Street address |
215 First Street
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (4)
|
|
| Relations |
| BioProject |
PRJNA292017 |
| SRA |
SRP062069 |
Less...
More...